NUL

Nul Health Limited, based in the UK, specializes in science-based treatment solutions aimed at helping individuals reduce alcohol consumption through personalized coaching and medication. Nul Health Limited is focused on providing innovative treatment options for alcohol consumption reduction. Founded in 2024 in London, UK, the company has completed one deal, raising EUR 840,000 in Seed funding on February 16, 2026, with DMG Ventures as the lead investor. The founder's history is not detailed, and there is no mention of any parent or subsidiary relationships.

Nul provides a comprehensive suite of science-based treatment options designed to help individuals reduce their alcohol consumption. Their core offerings include personalized coaching sessions and medication, which are integrated to support clients in their journey towards mindful drinking and overall well-being. By utilizing a combination of expert-led therapy and tailored treatment programs, Nul aims to empower individuals in various stages of their alcohol consumption reduction journey, whether they seek to cut back or quit entirely. The services are designed for a diverse customer base that includes individuals looking for a supportive environment free of stigma.

Nul operates primarily within the UK market, with a focus on delivering discreet treatment options directly to consumers' homes, ensuring accessibility and convenience. Nul's revenue model is structured around providing personalized treatment programs that may involve subscription services for ongoing coaching and medication. Clients typically engage with Nul by completing an initial survey to assess their goals, followed by consultation sessions with clinicians or therapists to determine suitable treatment options. This direct-to-consumer approach allows Nul to maintain a relationship with users throughout their treatment journey.

Revenue is generated through the sale of treatment programs, which may encompass both medication and therapeutic services, providing a cohesive solution for individuals seeking to improve their relationship with alcohol. The company’s partnership with Blueco Healthcare enhances its service delivery, ensuring compliance with healthcare standards and facilitating streamlined clinical services. In February 2026, Nul Health Limited raised EUR 840,000 in Seed funding led by DMG Ventures, with participation from individual investors. The funding will be utilized to complete its commercial launch in the United Kingdom, hire clinical and product staff, grow its customer base, and prepare for expansion into international markets.